Japan In Talks With Baxter, GSK For Emergency Flu Vaccines
This article was originally published in PharmAsia News
Executive Summary
Japan's Health Ministry is conducting separate talks with a pair of international drug makers to provide vaccines to prevent a pandemic of new virulent flu strains. Baxter International of the United States and GlaxoSmithKline of the United Kingdom have held talks with the ministry about getting marketing approval in Japan that would allow them to begin shipping supplies within three to six months after they apply. Both companies already have received orders for pre-pandemic flu vaccines from the U.S. and U.K. governments. (Click here for more - a subscription may be required
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.